Alx Oncology Holdings
$ 2.45
1.24%
24 Feb - close price
- Market Cap 321,433,000 USD
- Current Price $ 2.45
- High / Low $ 2.65 / 2.37
- Stock P/E N/A
- Book Value 0.84
- EPS -2.01
- Next Earning Report 2026-02-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -1.19 %
- 52 Week High 2.66
- 52 Week Low 0.40
About
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.
Analyst Target Price
$3.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-12 | 2025-05-07 | 2025-03-05 | 2024-11-11 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-13 | 2023-08-10 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.41 | -0.49 | -0.4773 | -0.4401 | -0.58 | -0.76 | -0.71 | -0.93 | -1.24 | -0.84 | -0.74 | -0.75 |
| Estimated EPS | -0.37 | -0.43 | -0.309 | -0.3902 | -0.78 | -0.77 | -0.84 | -0.84 | -0.87 | -0.88 | -0.8 | -0.89 |
| Surprise | -0.04 | -0.06 | -0.1683 | -0.0499 | 0.2 | 0.01 | 0.13 | -0.09 | -0.37 | 0.04 | 0.06 | 0.14 |
| Surprise Percentage | -10.8108% | -13.9535% | -54.466% | -12.7883% | 25.641% | 1.2987% | 15.4762% | -10.7143% | -42.5287% | 4.5455% | 7.5% | 15.7303% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.38 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALXO
2026-02-21 15:43:36
ALX Oncology (ALXO) is projected to release its Q4 2025 earnings before the market opens on Friday, February 27, 2026, with analysts anticipating a loss of ($0.38) per share. The company's stock recently traded down 5.8% to $2.45, giving it a market capitalization of $132.84 million. Insider activity shows Director Corey S. Goodman acquired over 3 million shares, increasing his stake to approximately 21% of the company's stock, while institutional investors also hold a significant portion.
2026-02-21 07:53:02
ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received an average "Moderate Buy" rating from six brokerages, with an average one-year target price of $2.50. This consensus includes four buy ratings, one hold, and one sell recommendation. Insider activity shows Director Corey S. Goodman recently purchased over 3.1 million shares, significantly increasing his stake, and institutional investors also modified their holdings.
2026-02-20 11:41:55
ALX Oncology (ALXO) is advancing its clinical pipeline with key 2026 data readouts expected for its lead candidates, Evorpacept and ALX2004. Following a $150 million financing round in January 2026, the company has extended its cash runway through the first half of 2028 to support trials in gastric, breast, and lung cancers.
2026-02-20 06:11:00
ALX Oncology Holdings Inc. is advancing two clinical-stage cancer treatments, Evorpacept and ALX2004, with significant data readouts expected in the near future. Evorpacept, a CD47-targeted therapy, has shown promising results in trials for HER2-positive gastric cancer and metastatic breast cancer. ALX2004, designed to enhance antibody-drug conjugates, is currently in a phase 1 trial with initial safety updates anticipated in the first half of 2026, while the company maintains a strong cash position to fund operations through mid-2028.
2026-02-20 02:57:14
ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026, before market open. The company will host a teleconference at 5:30am PT / 8:30am ET to discuss these results. Details for webcast access and participant listening options are provided for investors and interested parties.
2026-02-19 22:36:35
ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced it will report its fourth quarter and full year 2025 financial results and provide a business update on Friday, February 27, 2026, before market open. The company will host a teleconference and webcast at 5:30 AM PT / 8:30 AM ET to discuss these results. ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer, with lead candidate evorpacept and a second candidate ALX2004 currently in clinical trials.
